{"id":45402,"date":"2012-05-25T18:25:01","date_gmt":"2012-05-25T18:25:01","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/freedom-study-data-patients-experience-sustained-quality-of-life-benefits-with-more-frequent-home-hemodialysis-with.php"},"modified":"2012-05-25T18:25:01","modified_gmt":"2012-05-25T18:25:01","slug":"freedom-study-data-patients-experience-sustained-quality-of-life-benefits-with-more-frequent-home-hemodialysis-with","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/freedom\/freedom-study-data-patients-experience-sustained-quality-of-life-benefits-with-more-frequent-home-hemodialysis-with.php","title":{"rendered":"FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with &#8230;"},"content":{"rendered":"<p><p>    LAWRENCE, Mass., May 24, 2012 \/PRNewswire\/ --NxStage  Medical, Inc. (NXTM),    a leading manufacturer of innovative dialysis products, today    announced the latest interim findings from its FREEDOM (Following Rehabilitation, Economics    and Everyday-Dialysis Outcome Measurements) Study, which    found daily home hemodialysis treatments with the NxStage System One are associated with    long-term improvements in various physical and mental quality    of life measures. These interim FREEDOM Study results, \"At-Home    Short Daily Hemodialysis Improves the Long-Term Health-Related    Quality of Life,\" were published online on Kidney International's website in    advance of its release in print.  <\/p>\n<p>    (Logo: <a href=\"http:\/\/photos.prnewswire.com\/prnh\/20110503\/MM94799LOGO\" rel=\"nofollow\">http:\/\/photos.prnewswire.com\/prnh\/20110503\/MM94799LOGO<\/a>    )  <\/p>\n<p>    NxStage's FREEDOM Study is the largest prospective study of    frequent home hemodialysis to date. The FREEDOM Study reported    improvements in several quality of life measures in end stage    renal disease (ESRD) patients at 12 months of follow-up,    including:  <\/p>\n<p>    \"Today's data shows more frequent home hemodialysis unlocks a    variety of clinical and quality of life benefits for ESRD    patients that remain over an extended period of time,\" said    Frederic Finkelstein, MD, Chief of Nephrology at the Hospital    of St. Raphael in New Haven, Conn. and Clinical Professor of    Medicine at Yale University Medical School, as well as the    study's primary author. \"ESRD patients struggle on a daily    basis with maintaining their overall health while trying to    better manage their chronic condition. This data shows that    more frequent home hemodialysis can have a positive impact on a    patient's perception of his quality of life.\"  <\/p>\n<p>    \"This recent data builds upon an already robust mountain of    clinical evidence pointing to the benefits of more frequent    home hemodialysis,\" said Jeffrey H. Burbank, Chief Executive    Officer of NxStage Medical, Inc. \"FREEDOM continues to show    that more frequent home therapy with the NxStage System One    transforms patient lives for the better, resulting in    healthier, happier patients who are empowered in their own    healthcare.\"  <\/p>\n<p>    About the NxStage System One  <\/p>\n<p>    The NxStage System One is the first and only truly portable    hemodialysis system cleared for home use by the U.S. Food &    Drug Administration (FDA). Its simplicity and revolutionary    size (just over a foot tall) are intended to allow convenient    use in patients' homes and give patients the freedom to travel    with their therapy. When combined with the NxStage    Pureflow SL Dialysis Preparation System, patients are able to    further simplify, using ordinary tap water to create dialysis    fluid on demand. Unlike conventional hemodialysis    systems, the System One requires no special infrastructure to    operate. Under the guidance of their physician, patients can    use the NxStage System One, with their trained partners, where,    how and when it best meets their needs, at home or on vacation.    <a href=\"http:\/\/www.nxstage.com\/\" rel=\"nofollow\">http:\/\/www.nxstage.com\/<\/a>.  <\/p>\n<p>    About NxStage Medical  <\/p>\n<p>    NxStage Medical, Inc. (NXTM)    is a medical device company, headquartered in Lawrence,    Massachusetts, USA, that develops, manufactures and markets    innovative systems for the treatment of ESRD and acute kidney    failure. For more information on NxStage and its products,    please visit the company's website at <a href=\"http:\/\/www.nxstage.com\/\" rel=\"nofollow\">http:\/\/www.nxstage.com\/<\/a>.  <\/p>\n<p>    Forward-Looking Statements  <\/p>\n<\/p>\n<p>Read more:<\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/freedom-study-data-patients-experience-185900098.html;_ylt=A2KJjahrzr9P4HkApqP_wgt.\" title=\"FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with ...\">FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits with More Frequent Home Hemodialysis with ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> LAWRENCE, Mass., May 24, 2012 \/PRNewswire\/ --NxStage Medical, Inc. (NXTM), a leading manufacturer of innovative dialysis products, today announced the latest interim findings from its FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study, which found daily home hemodialysis treatments with the NxStage System One are associated with long-term improvements in various physical and mental quality of life measures. These interim FREEDOM Study results, \"At-Home Short Daily Hemodialysis Improves the Long-Term Health-Related Quality of Life,\" were published online on Kidney International's website in advance of its release in print <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/freedom\/freedom-study-data-patients-experience-sustained-quality-of-life-benefits-with-more-frequent-home-hemodialysis-with.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[30],"tags":[],"class_list":["post-45402","post","type-post","status-publish","format-standard","hentry","category-freedom"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/45402"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=45402"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/45402\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=45402"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=45402"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=45402"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}